FORM 4

obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

wasnington,	D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Arbuckle Stuart A (Last) (First) (Middle)						Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX] Date of Earliest Transaction (Month/Day/Year)								Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) below)					
C/O VERTEX PHARMACEUTICALS INCORPORATED						12/13/2023 4. If Amendment, Date of Original Filed (Month/Day/Year)							6.1	EVP, COO 6. Individual or Joint/Group Filing (Check Applicable					
50 NORTHERN AVENUE					,							Lin	Line) X Form filed by One Reporting Person						
(Street) BOSTON	N M	A	02210			Form filed by More than One Reporting Person Rule 10b5-1(c) Transaction Indication												rting	
(City) (State) (Zip)					X														
		Tab	le I - No	n-Deriv	vative	Sec	curit	ies Ac	quired	, Dis	posed o	of, or Be	neficial	ly Owne	d				
1. Title of Security (Instr. 3) 2. Trans. Date (Month/I				Execution Date,			3. Transactio Code (Inst					Benefic Owned	es ally Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	ction(s)			(Instr. 4)		
Common Stock 12				12/13	3/2023				M		8,603	A	\$187.	53 65	65,159		D		
Common Stock 12			12/13	3/2023				S ⁽¹⁾		8,603	D	\$399	56	56,556		D			
Common Stock												1	140		I	401(k)			
		T	able II -								osed of converti			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	n Date,	4. Transa Code (8)		n of E		Expiration	6. Date Exercis: Expiration Date (Month/Day/Yea		7. Title an Amount of Securities Underlyin Derivative (Instr. 3 a	of G G Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$187.53	12/13/2023			M			8,603	(2)		02/05/2029	Common Stock	8,603	\$0	0		D		

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Mr.\ Arbuckle's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1,\ which\ was\ entered\ into\ on\ 02/28/2023.$
- 2. Fully vested.

Remarks:

/s/ Christiana Stevenson, Attorney-in-Fact 12/15/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.